China Resources Pharma announced plans to raise $368.5 million for a China life science investment fund.
Deals and Financings
- China Resources Pharmaceutical announced plans to raise $368.5 million for a China life science investment fund;
- Chi-Med (Hutchison China MediTech) completed a $301 million secondary offering of its US shares to support its drug development program;
- Maxhealth Medicine of Wuxi, China struck a deal with Switzerland’s Legacy Healthcare to commercialize Legacy’s hair loss treatment in China;
Trials and Approvals
- Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine, which it developed with the Bioengineering Institute of the Chinese Academy of Military Medical Sciences;
- Suzhou’s MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of its second-generation PD-L1 antibody;
- Denovo Biopharma, a San Diego-Beijing company, announced approval to conduct a US arm of China-US Phase III trial for its lead lymphoma drug;
- Transgene reported its therapeutic hepatitis B vaccine was safe and promoted immunogenicity in a Phase I/Ib trial in Europe; the vaccine is expected to start China trials soon;
- BeyondSpring of New York enrolled the first patient in the China arm of a global Phase II/III clinical trial of plinabulin to prevent chemotherapy-induced neutropenia.
